All In Biotech

Drug Trial Radar · NCT01462344

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma

Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 6,250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,250

Actual

Start

Nov 17, 2011

Primary completion

Nov 1, 2015

Study completion Nov 3, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Parexel
First posted
Oct 31, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.

Conditions

  • Asthma

Interventions

  • ADVAIR 100/50mcgDrug

    fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months

  • ADVAIR 250/50mcgDrug

    fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months

  • FLOVENT 100mcgDrug

    fluticasone propionate (100) twice daily (AM and PM) for 6 months

  • FLOVENT 250mcgDrug

    fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)Time frame: From Day 1 up to 6 months
  2. Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment PeriodTime frame: From Day 1 up to 6 months

Locations

530 sites in 32 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Montgomery, Alabama

  • GSK Investigational Site

    Scottsboro, Alabama

  • GSK Investigational Site

    Toney, Alabama

  • GSK Investigational Site

    Tuscaloosa, Alabama

  • GSK Investigational Site

    Dothan, Alaska

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Bentonville, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Alhambra, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Canoga Park, California

  • GSK Investigational Site

    Dinuba, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Gold River, California

  • GSK Investigational Site

    Granada Hills, California

  • GSK Investigational Site

    Harbor City, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Huntington Park, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Napa, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Orange, California

  • GSK Investigational Site

    Palmdale, California

  • GSK Investigational Site

    Paramount, California

Showing 40 of 530 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.